07:25 AM EST, 02/18/2026 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) reported a full-year 2025 net loss Wednesday of $203.8 million, narrower than net loss of $241.6 million in the previous year.

Revenue for 2025 was $22.5 million, down from $45.6 million a year earlier.

Analysts polled by FactSet expected revenue of $27.2 million.

The company said it had $728.9 million in cash and or cash equivalents on hand as of Dec. 31.